UCB’s Cimzia Could Be Delayed Until 2008 Or Later For Crohn’s
This article was originally published in The Pink Sheet Daily
Executive Summary
A key regulatory concern for the biologic is a lack of induction evaluation criteria in one of two pivotal Crohn’s trials, the firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Centocor President Neal Fowler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the anti-TNF market and the entry of Abbott’s Humira – the first competitor for Remicade – in Crohn’s disease.
Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
UCB Receives “Complete Response” Letter For Cimzia
Firm says FDA seeks new information and clarification regarding the BLA.